| Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... New England journal of medicine 369 (2), 134-144, 2013 | 4249 | 2013 |
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid, R Kefford, JS Weber, ... The Lancet 384 (9948), 1109-1117, 2014 | 2161 | 2014 |
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ... Nature 487 (7408), 500-504, 2012 | 2028 | 2012 |
| Association of pembrolizumab with tumor response and survival among patients with advanced melanoma A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ... Jama 315 (15), 1600-1609, 2016 | 1184 | 2016 |
| Evaluation of immune-related response criteria and RECIST v1. 1 in patients with advanced melanoma treated with pembrolizumab FS Hodi, WJ Hwu, R Kefford, JS Weber, A Daud, O Hamid, A Patnaik, ... Journal of Clinical Oncology 34 (13), 1510-1517, 2016 | 782 | 2016 |
| Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra AR Tate, J Underwood, DM Acosta, M Julià‐Sapé, C Majós, ... NMR in Biomedicine 19 (4), 411-434, 2006 | 296 | 2006 |
| Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. A Ribas, C Robert, FS Hodi, JD Wolchok, AM Joshua, WJ Hwu, JS Weber, ... Journal of Clinical Oncology 33 (15_suppl), 3001-3001, 2015 | 247 | 2015 |
| Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). A Ribas, FS Hodi, R Kefford, O Hamid, A Daud, JD Wolchok, WJ Hwu, ... Journal of Clinical Oncology 32 (18_suppl), LBA9000-LBA9000, 2014 | 202 | 2014 |
| Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. R Kefford, A Ribas, O Hamid, C Robert, A Daud, JD Wolchok, AM Joshua, ... Journal of Clinical Oncology 32 (15_suppl), 3005-3005, 2014 | 118 | 2014 |
| Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. A Daud, A Ribas, C Robert, FS Hodi, JD Wolchok, AM Joshua, WJ Hwu, ... Journal of Clinical Oncology 33 (15_suppl), 9005-9005, 2015 | 102 | 2015 |
